ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2020
A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab.
Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01732770 (A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates), which is not on this map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Beyond bone effects: the role of denosumab in muscle Health - A systematic review.Aging clinical and experimental research · 2026Pooled it
- Diagnosis and management of osteoporosis in Saudi Arabia: 2023 key updates from the Saudi Osteoporosis Society.Archives of osteoporosis · 2023Pooled it
- Anti-resorptive and anabolic therapies improve Falls Risk Assessment Score (FRAS) in postmenopausal women with type 2 diabetes mellitus.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Trial
- Position paper: a coordinated approach to fracture and fall prevention from seven international organizations.European geriatric medicine · 2026Article
- Real-world effectiveness of denosumab compared to teriparatide in patients with severe osteoporosis.Frontiers in endocrinology · 2026Article
- Pain in Osteoporosis: Current and Future Strategies.Drugs & aging · 2025Review
- Calf circumference predicts changes of bone mineral density in postmenopausal osteoporotic women receiving denosumab.Aging clinical and experimental research · 2025Article
- Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal Muscle.Current osteoporosis reports · 2024Review
- Among people on osteoporosis medication, loss of appendicular or total body lean mass is an independent risk factor for hip and major osteoporotic fractures.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Article
- Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies.ESMO open · 2024Article
- Therapeutic advantage of teriparatide in very elderly patients with proximal femoral fractures: a functional and BMD analysis.BMC musculoskeletal disorders · 2024Article
- The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena.Archives of osteoporosis · 2024Article
- Bone involvement in the early stages of Parkinson's disease: a case-control study.The Journal of international medical research · 2024Article
- The Interconnection Between Muscle and Bone: A Common Clinical Management Pathway.Calcified tissue international · 2024Review
- Sclerostin: clinical insights in muscle-bone crosstalk.The Journal of international medical research · 2023Review
- Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Article
- Is sarcopenia associated with osteoporosis? A cross-sectional study of 262 women with hip fracture.European journal of physical and rehabilitation medicine · 2022Article
- Skeletal Aging.Mayo Clinic proceedings · 2022Review
- What are the efficacy and safety of bisphosphonates and RANK-ligand-inhibitors for men with prostate cancer and bone metastases? - A Cochrane Review summary with commentary.Journal of musculoskeletal & neuronal interactions · 2021Article
- Pharmacologic Interventions for Fracture Risk Reduction in the Oldest Old: What Is the Evidence?JBMR plus · 2021Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
Abstract
Recent studies suggest that the RANK/RANKL system impacts muscle function and/or mass. In the pivotal placebo-controlled fracture trial of the RANKL inhibitor denosumab in women with postmenopausal osteoporosis, treatment was associated with a lower incidence of non-fracture-related falls (p = 0.02). This ad hoc exploratory analysis pooled data from five placebo-controlled trials of denosumab to determine consistency across trials, if any, of the reduction of fall incidence. The analysis included trials in women with postmenopausal osteoporosis and low bone mass, men with osteoporosis, women receiving adjuvant aromatase inhibitors for breast cancer, and men receiving androgen deprivation therapy for prostate cancer. The analysis was stratified by trial, and only included data from the placebo-controlled period of each trial. A time-to-event analysis of first fall and exposure-adjusted subject incidence rates of falls were analyzed. Falls were reported and captured as adverse events. The analysis comprised 10,036 individuals; 5030 received denosumab 60 mg subcutaneously once every 6 months for 12 to 36 months and 5006 received placebo. Kaplan-Meier estimates showed an occurrence of falls in 6.5% of subjects in the placebo group compared with 5.2% of subjects in the denosumab group (hazard ratio = 0.79; 95% confidence interval 0.66-0.93; p = 0.0061). Heterogeneity in study designs did not permit overall assessment of association with fracture outcomes. In conclusion, denosumab may reduce the risk of falls in addition to its established fracture risk reduction by reducing bone resorption and increasing bone mass. These observations require further exploration and confirmation in studies with muscle function or falls as the primary outcome. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research..
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.